Voloridge Investment Management
ALNY icon

Voloridge Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Voloridge Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Sell
4,500
-184,717
-98% -$55.7M 0.01% 690
2026
Q1 		$62.6M Buy
189,217
+28,640
+18% +$9.75M 0.25% 104
2025
Q4 		$63.9M Sell
160,577
-196,229
-55% -$86.8M 0.22% 113
2025
Q3 		$163M Buy
356,806
+349,104
+4,533% +$142M 0.55% 27
2025
Q2 		$2.51M Sell
7,702
-54,600
-88% -$15.1M 0.01% 912
2025
Q1 		$16.8M Buy
62,302
+45,526
+271% +$11.7M 0.06% 411
2024
Q4 		$3.95M Sell
16,776
-177,471
-91% -$46.7M 0.01% 834
2024
Q3 		$53.4M Buy
194,247
+179,384
+1,207% +$46.7M 0.19% 147
2024
Q2 		$3.61M Buy
+14,863
New +$2.35M 0.01% 833
2023
Q4 		– Sell
-37,412
Closed -$6.63M – 1138
2023
Q3 		$6.63M Sell
37,412
-37,446
-50% -$7.14M 0.03% 572
2023
Q2 		$14.2M Sell
74,858
-66,530
-47% -$13.2M 0.07% 375
2023
Q1 		$28.3M Sell
141,388
-68,623
-33% -$14.4M 0.14% 214
2022
Q4 		$49.9M Buy
210,011
+138,481
+194% +$29.5M 0.28% 83
2022
Q3 		$14.3M Buy
+71,530
New +$13.6M 0.08% 343
2022
Q2 		– Sell
-29,380
Closed -$4.8M – 1408
2022
Q1 		$4.8M Buy
+29,380
New +$4.48M 0.03% 654
2021
Q4 		– Sell
-12,506
Closed -$2.36M – 1556
2021
Q3 		$2.36M Buy
+12,506
New +$2.35M 0.02% 996
2020
Q1 		– Sell
-38,410
Closed -$4.42M – 1065
2019
Q4 		$4.42M Buy
+38,410
New +$3.83M 0.09% 306
2018
Q2 		– Sell
-78,483
Closed -$9.35M – 398
2018
Q1 		$9.35M Buy
78,483
+65,470
+503% +$8.44M 0.22% 83
2017
Q4 		$1.65M Sell
13,013
-109,244
-89% -$13.7M 0.04% 337
2017
Q3 		$14.4M Sell
122,257
-14,405
-11% -$1.23M 0.32% 73
2017
Q2 		$10.9M Buy
+136,662
New +$8.73M 0.27% 101
2014
Q2 		– Sell
-8,898
Closed -$597K – 87
2014
Q1 		$597K Buy
+8,898
New +$689K 0.08% 63

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voloridge Investment Management's ALNY Position: Q2 2026 in Review

Voloridge Investment Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 98% in Q2 2026, selling an estimated $55.7M and leaving 4,500 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #690.

Voloridge Investment Management first reported a position in ALNY in Q1 2014 and has held it in 22 quarters since. The position peaked at $163M in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Voloridge Investment Management held 4,500 shares of Alnylam Pharmaceuticals worth $1.35M as of Q2 2026.
  • Voloridge Investment Management sold 184,717 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $55.7M.
  • Alnylam Pharmaceuticals made up 0.01% of Voloridge Investment Management's portfolio in Q2 2026, its #690 holding.
  • Voloridge Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and has held it in 22 quarters since.
  • Voloridge Investment Management's Alnylam Pharmaceuticals position peaked at $163M in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.